Suppr超能文献

家族史对前列腺癌风险的影响:对临床管理的意义。

The influence of family history on prostate cancer risk: implications for clinical management.

机构信息

Department of Urology and Andrology, Danube Hospital, Vienna, AustriaDepartment of Urology, Hospital Clinic Department of Urology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, SpainDivision of Surgery and Interventional Science, University College London (UCL) Hospitals NHS Foundation Trust/UCL Comprehensive Biomedical Research Centre, London, UKDepartment of Urology, Academic Hospital, Braunschweig, GermanyDepartment of Urology and Andrology, Hospital St. John of God, Vienna, AustriaDepartment of Urology, Erasmus Medical Center, University Medical Centre, Rotterdam, The NetherlandsDepartment of Urology, Sant'Andrea Hospital 2nd School of Medicine, 'La Sapienza' University of Rome, Rome, Italy.

出版信息

BJU Int. 2011 Mar;107(5):716-721. doi: 10.1111/j.1464-410X.2010.10024.x. Epub 2010 Dec 16.

Abstract

• The most recent evidence for the link between a family history of prostate cancer and individual risk for future disease was examined, with the aim of understanding what the existence and nature of a family history of prostate cancer does to a man's risk of developing the disease. • Our findings highlighted the clear association between a family history of prostate cancer and increased risk of developing the disease; with a greater proximity of relatedness, greater number of family members affected and/or earlier age at diagnosis of the family member elevating risk further. • These findings have important clinical implications for the identification and subsequent management of men deemed to be at increased risk of developing prostate cancer. The evidence for prostate cancer risk reduction with the mono 5α-reductase inhibitor (5ARI) finasteride in a low-risk population and, more recently, with the dual 5ARI dutasteride in a population at increased risk of developing the disease, has potential to expand management options for men at risk of developing prostate cancer beyond more frequent and/or earlier surveillance. • Given that family history can be easily assessed in routine clinical practice, it should be regarded as an important parameter to consider alongside PSA level for prostate cancer risk assessment.

摘要

• 研究了家族前列腺癌病史与个体未来疾病风险之间的最新关联证据,旨在了解家族前列腺癌病史对男性患该病风险的影响。• 我们的研究结果强调了家族前列腺癌病史与疾病风险增加之间的明显关联;亲属关系越近、受影响的家庭成员越多和/或家族成员诊断年龄越早,风险进一步升高。• 这些发现对确定和随后管理被认为有患前列腺癌风险的男性具有重要的临床意义。在低危人群中使用单 5α-还原酶抑制剂(5ARI)非那雄胺和最近在高危人群中使用双 5ARI 度他雄胺降低前列腺癌风险的证据,有可能将有患前列腺癌风险男性的管理选择扩大到更频繁和/或更早的监测之外。• 鉴于家族史在常规临床实践中易于评估,因此应将其视为与 PSA 水平一起评估前列腺癌风险的重要参数。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验